Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hamburg, Germany
Anchor Academic Publishing
2014
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 |
| Beschreibung: | Online resource; title from PDF cover (ebrary, viewed April 15, 2014) |
| Beschreibung: | 1 online resource (283 pages) illustrations (some color) |
| ISBN: | 9783954896875 3954896877 9783954891870 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043785642 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160920s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9783954896875 |9 978-3-95489-687-5 | ||
| 020 | |a 3954896877 |9 3-95489-687-7 | ||
| 020 | |a 9783954891870 |9 978-3-95489-187-0 | ||
| 035 | |a (ZDB-4-EBA)ocn878147377 | ||
| 035 | |a (OCoLC)878147377 | ||
| 035 | |a (DE-599)BVBBV043785642 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 572 |2 23 | |
| 100 | 1 | |a Osmane, Malik |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |c Malik Osmane |
| 264 | 1 | |a Hamburg, Germany |b Anchor Academic Publishing |c 2014 | |
| 264 | 4 | |c © 2014 | |
| 300 | |a 1 online resource (283 pages) |b illustrations (some color) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Online resource; title from PDF cover (ebrary, viewed April 15, 2014) | ||
| 650 | 7 | |a SCIENCE / Life Sciences / Biochemistry |2 bisacsh | |
| 650 | 7 | |a Biological products |2 fast | |
| 650 | 7 | |a Drugs / Generic substitution |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology industry |2 fast | |
| 650 | 4 | |a Biological products |a Drugs |x Generic substitution |a Pharmaceutical biotechnology industry | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Osmane, Malik |t Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029196702 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=773129 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=773129 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176621361430529 |
|---|---|
| any_adam_object | |
| author | Osmane, Malik |
| author_facet | Osmane, Malik |
| author_role | aut |
| author_sort | Osmane, Malik |
| author_variant | m o mo |
| building | Verbundindex |
| bvnumber | BV043785642 |
| collection | ZDB-4-EBA |
| ctrlnum | (ZDB-4-EBA)ocn878147377 (OCoLC)878147377 (DE-599)BVBBV043785642 |
| dewey-full | 572 |
| dewey-hundreds | 500 - Natural sciences and mathematics |
| dewey-ones | 572 - Biochemistry |
| dewey-raw | 572 |
| dewey-search | 572 |
| dewey-sort | 3572 |
| dewey-tens | 570 - Biology |
| discipline | Biologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02082nmm a2200433zc 4500</leader><controlfield tag="001">BV043785642</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160920s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783954896875</subfield><subfield code="9">978-3-95489-687-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3954896877</subfield><subfield code="9">3-95489-687-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783954891870</subfield><subfield code="9">978-3-95489-187-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn878147377</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)878147377</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043785642</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">572</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Osmane, Malik</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account</subfield><subfield code="c">Malik Osmane</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hamburg, Germany</subfield><subfield code="b">Anchor Academic Publishing</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (283 pages)</subfield><subfield code="b">illustrations (some color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Online resource; title from PDF cover (ebrary, viewed April 15, 2014)</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SCIENCE / Life Sciences / Biochemistry</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biological products</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Generic substitution</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical biotechnology industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological products</subfield><subfield code="a">Drugs</subfield><subfield code="x">Generic substitution</subfield><subfield code="a">Pharmaceutical biotechnology industry</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Osmane, Malik</subfield><subfield code="t">Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029196702</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=773129</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=773129</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043785642 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:35:04Z |
| institution | BVB |
| isbn | 9783954896875 3954896877 9783954891870 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029196702 |
| oclc_num | 878147377 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource (283 pages) illustrations (some color) |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Anchor Academic Publishing |
| record_format | marc |
| spelling | Osmane, Malik Verfasser aut Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane Hamburg, Germany Anchor Academic Publishing 2014 © 2014 1 online resource (283 pages) illustrations (some color) txt rdacontent c rdamedia cr rdacarrier Online resource; title from PDF cover (ebrary, viewed April 15, 2014) SCIENCE / Life Sciences / Biochemistry bisacsh Biological products fast Drugs / Generic substitution fast Pharmaceutical biotechnology industry fast Biological products Drugs Generic substitution Pharmaceutical biotechnology industry Erscheint auch als Druck-Ausgabe Osmane, Malik Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| spellingShingle | Osmane, Malik Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account SCIENCE / Life Sciences / Biochemistry bisacsh Biological products fast Drugs / Generic substitution fast Pharmaceutical biotechnology industry fast Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| title | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_auth | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_exact_search | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_full | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_fullStr | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_full_unstemmed | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account Malik Osmane |
| title_short | Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| title_sort | rift lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account |
| topic | SCIENCE / Life Sciences / Biochemistry bisacsh Biological products fast Drugs / Generic substitution fast Pharmaceutical biotechnology industry fast Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| topic_facet | SCIENCE / Life Sciences / Biochemistry Biological products Drugs / Generic substitution Pharmaceutical biotechnology industry Biological products Drugs Generic substitution Pharmaceutical biotechnology industry |
| work_keys_str_mv | AT osmanemalik riftlineswithineuropeanregulatoryframeworkforbiosimilarswhentakingheterogeneityandvariationduringlifecycleofthereferencebiologicandthebiosimilarintoaccount |